Study on TSR-042 in Advanced Clear Cell Sarcoma
Phase II,single arm study designed to explore the activity of TSR-042, an immunotherapy agent, in patients with a diagnosis of advanced or metastatic clear cell sarcoma (CCS).
Sarcoma, Clear Cell
DRUG: TSR-042
Overall Response Rate, Response rate according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, At week 12
Immune-related RECIST (ir-RECIST) response rate, Response rate according ir-RECIST criteria, At weeks 6, 12, 24, 36, 48, 60, 72, 84, 96|Choi criteria response rate, Response rate according Choi criteria, At weeks 6, 12, 24, 36, 48, 60, 72, 84, 96|Progression Free Survival (PFS), Survival without disease progression, At 3 and 5 years|Overall Survival, Proportion of patients who are still alive at 36 and 60 months after have started the treatment, At 3 and 5 years|Clinical Benefit Rate, Proportion of patients who experienced Complete Response, Progression Response or Stable Disease for over 6 months, Month 6|Adverse events related to the treatment, Safety in term of grading of adverse event is evaluate from the firs treatment dose throughout the study according to CTCAE 5.0, Week 3, week 6, week 9, week 12, week 18, week 24, week 36, week 48, week 60, week 72|Growth Modulation Index (GMI), Correlation between response and prior disease medical treatment: ratio of time to progression with the nth line of therapy to the those with the n-1th line., At weeks 6, 12, 24, 36, 48, 60, 72, 84, 96|Quality of Life according the 30 questions European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Evaluation of the quality of life collected with European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, Day1 Cycle 2, Day 1 Cycle 3, Every 3 cycles (Day1Cyle6, Day1Cycle 9, …) and through study completion, an average of 1 year|Quality of Life according the questionnaire Euro Quality Of Life 5 Domains (EQ-5D), Evaluation of the quality of life collected with Euro Quality Of Life 5 Domains (EQ-5D), Day1 Cycle 2, Day 1 Cycle 3, Every 3 cycles (Day1Cyle6, Day1Cycle 9, …) and through study completion, an average of 1 year|Safety according the Patient Reported Outcome according Common Terminology Criteria for Adverse Events (PRO-CTCAE), Evaluation of the quality of safety reported by the patient with the PRO-CTCAE, Day1 Cycle 2, Day 1 Cycle 3, Every 3 cycles (Day1Cyle6, Day1Cycle 9, …) and through study completion, an average of 1 year
Expression level of PD1 and PDL1 at pre-treatment evaluated on cancer cells and in tumor infiltrating myeloid cells, Analysis of immune contexture in pretreatment tumor tissue., Day1 (pre-treatment)|Frequency in the expression of myeloid-derived suppressor cells in peripheral blood mononuclear cell, Immunological monitoring of peripheral blood immune subsets, to evaluate the systemic immunological status of patients,, Day1, day15, day45 of treatment and through study completion, an average of 1 year|Frequency in the expression of anti-tumor immune cells in PBMC collected at baseline and during TSR-042., Immunological monitoring of peripheral blood immune subsets, to evaluate the systemic immunological status of patients,, Day1, day15, day45 of treatment and through study completion, an average of 1 year
Phase II, single arm, not randomized, European multicentric study designed to explore the activity of TSR-042, a human monoclonal anti-PD-1 inhibitor, in a population of patients with a diagnosis of advanced/metastatic clear cell sarcoma (CCS).